Search Results

Shanghai Henlius Biotech, Inc. (2696.HK) has entered into an exclusive license agreement with Intas Pharmaceuticals Limited (“Intas”) for the development and commercialisation in Europe and India for several indications including ES-SCLC, and specific formulation of HANSIZHUANG (serplulimab injection), Henlius’ novel anti-PD-1 mAb.

Following reports of destroyed and discarded data, the U.S. regulator issued a warning letter to India’s Intas Pharmaceuticals regarding violations of current good manufacturing practice.

The troubled Indian pharma company received its second FDA warning letter in months, which this time cited quality control and data integrity lapses at its manufacturing facility in Gujarat, India.

Today, Comera Life Sciences, Inc. (“Comera” or the “Company”) and Intas Pharmaceuticals Ltd. (“Intas”) announced a research collaboration to develop a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience.

Syna Therapeutics, a joint venture of Reig Jofre and Leanbio, today announces that it has signed a global licensing deal with Intas Pharmaceuticals Ltd. to commercialise its biosimilar drug LB-0702 to treat pathologies in the field of haematology.

Prestige Biopharma Limited and Intas Pharmaceuticals Limited announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige Biopharma’s bevacizumab biosimilar, in the US, Europe, Canada, MENA, Brazil, Mexico, South Africa, Thailand, Vietnam, Philippines, Malaysia, Singapore, Indonesia, Kyrgyzstan and Tajikistan.

Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced that Accord BioPharma, Inc., a subsidiary of Intas Pharmaceuticals Ltd, in the United States has received a notification that the US Food and Drug Administration (“FDA”) has accepted its Biologics License Application (BLA) for DMB-3115, a proposed biosimilar to Stelara® (Ustekinumab), for substantive review.

The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.